Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 3:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 333 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia (AML)
Interventions
ABBV-744
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Orange, California • Sacramento, California • Chicago, Illinois + 3 more
Conditions
Tumors
Interventions
CUDC-101
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
Interventions
PY314, Combination Therapy: PY314 + Pembrolizumab
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more
Conditions
Mucositis, Nephrotoxicity, Ototoxicity
Interventions
Tempol, Placebo Solution
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
La Jolla, California • Merced, California • San Francisco, California + 4 more
Conditions
Solid Tumors
Interventions
MEDI9253, Durvalumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 101 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
St Louis, Missouri • Buffalo, New York • New York, New York + 1 more
Conditions
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric Cancer, Hepatecellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Mesothelioma, Pancreatic Carcinoma Metastatic, Hormone Refractory Prostate Cancer, Soft Tissue Sarcomas
Interventions
SHY-ONC6
Drug
Lead sponsor
SHY Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Scottsdale, Arizona • Denver, Colorado • Houston, Texas + 1 more
Conditions
EWINGS SARCOMA
Interventions
Rabbit anti-thymocyte globulin, Busulfan, Melphalan, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
University of Louisville
Other
Eligibility
Up to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Cancer
Interventions
XL647
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Stanford, California • Rochester, Minnesota
Conditions
Non-Small Cell Lung Cancer
Interventions
Rilvegostomig, Ramucirumab, Dato-DXd
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Santa Monica, California • Santa Rosa, California • Atlanta, Georgia + 3 more
Conditions
Tumors
Interventions
Mirvetuximab soravtansine
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Fairway, Kansas • Boston, Massachusetts • Detroit, Michigan + 6 more
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Conditions
Solid Tumor, Adult
Interventions
SM08502
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 14 more
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Navitoclax, Positron Emission Tomography, Trametinib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Conditions
Pancreatic Neoplasm
Interventions
Antroquinonol
Drug
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Tampa, Florida • Newnan, Georgia • Detroit, Michigan + 2 more
Completed Phase 1Phase 2 Interventional Results available

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

NCT03611556
Conditions
Carcinoma, Metastatic Pancreatic Adenocarcinoma
Interventions
Oleclumab, Durvalumab, Gemcitabine, Nab-paclitaxel, Oxaliplatin, Folinic acid, 5-FU
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
La Jolla, California • Aurora, Colorado • Fort Myers, Florida + 14 more
Conditions
Advanced Hematologic Malignancies
Interventions
CPI-613
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Diffuse
Interventions
Vimseltinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
9
States / cities
Palo Alto, California • Denver, Colorado • Jacksonville, Florida + 5 more
Conditions
Advanced Solid Tumor, Metastatic Breast Cancer
Interventions
BTX-A51
Drug
Lead sponsor
Edgewood Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more
Conditions
Acute Myeloid Leukemia
Interventions
AZD1208
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Houston, Texas
Conditions
Cancer, Neoplasms, Tumors, Refractory Solid Tumors, Recurrent Solid Tumors
Interventions
IT-141
Drug
Lead sponsor
Intezyne Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Dallas, Texas • Seattle, Washington
Completed Phase 1 Interventional Accepts healthy volunteers

ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study

NCT03082690
Conditions
HIV Prevention
Interventions
DuoGel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Neoplasms, Solid Tumor, Adult, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
Interventions
JNJ-64619178
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Sarasota, Florida • Boston, Massachusetts • Columbus, Ohio + 1 more
Conditions
Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions
Alisertib, Pazopanib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois